Efficacy of CBT-I With Adjuvant Melatonin in Older Adults Chronic Insomnia
- Sponsor
- The University of Hong Kong
- Study ID
- NCT07695246
- Status
- Recruiting
Conditions
- Aging
- Insomnia
- Sleep Disorders
Eligibility Criteria
- Sex
- ALL
- Age
- 60 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Cognitive behavioural therapy for insomnia — BEHAVIORALCBT-I is a multi-component, non-pharmacologic intervention that targets behavioural, cognitive, and physiological perpetuating factors of insomnia. Four group-based weekly sessions (120-min; 6-8 participants) will be delivered. Components: sleep psychoeducation, sleep hygiene, stimulus control, sleep restriction, relaxation training, cognitive restructuring (addressing dysfunctional beliefs about sleep), and relapse prevention. Delivered in-person by trained therapists supervised weekly by the PI.
- Melatonin 3 mg immediate-release — DIETARY_SUPPLEMENTMelatonin is a safe and accessible sleep-promoting supplement. The tablet will be taken once daily, 30 minutes before habitual bedtime for 4 weeks, concurrent with CBT-I.
- Psychoeducation — BEHAVIORALFour group-based weekly sessions covering sleep hygiene, healthy diet, and exercise habits for older adults. This arm will not include any active therapeutic CBT-I components. It serves as the active control, controlling for attention and non-specific expectancy effects.
- Placebo Oral Tablet — DRUGPlacebo capsule identical in appearance to the melatonin capsule, taken once daily, 30 minutes before habitual bedtime for 4 weeks. Used in CBT-I + Placebo and Psychoeducation + Placebo arms.
Study Details
This study tests the efficacy of cognitive behavioural therapy for insomnia (CBT-I) with or without adjunct melatonin in older adults with insomnia. Adults aged 60 or above with chronic insomnia will be randomly assigned to one of three groups: (1) CBT-I plus nightly melatonin, (2) CBT-I plus nightly placebo tablet, or (3) sleep health psychoeducation plus nightly placebo tablet. All group sessions occur weekly for four weeks.
Key Dates
- First listed
- Jul 10, 2026
- Start date
- Aug 1, 2026
- Status verified
- Aug 2026
- Primary completion
- Aug 1, 2029
- Completion
- Aug 1, 2029
Study Design
- Enrollment
- 183 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: CBT-I + MelatoninFour weekly group-based CBT-I sessions (120-min, 6-8 participants) plus oral melatonin 3 mg immediate-release taken 30 min before habitual bedtime for 4 weeks.
- Active Comparator: CBT-I + PlaceboIdentical four weekly group-based CBT-I sessions plus placebo capsule (identical appearance) taken 30 min before habitual bedtime for 4 weeks.
- Placebo Comparator: Psychoeducation + PlaceboFour weekly group-based sleep psychoeducation sessions (sleep hygiene, healthy diet, and exercise for older adults; no active CBT-I components) plus placebo capsule for 4 weeks.
Primary Outcome Measure
Insomnia Symptoms - Insomnia Severity Index [ Time Frame: Baseline, Mid-session (Week 2 of the intervention), Post-Treatment (one-week after treatment conclusion) for all participants, and at Post-Treatment 3-month and Post-Treatment 6-month for participants in the treatment groups. ]
Central Contacts
- Shirley Xin LI, DClinPsy, PhD852 39177035
- Zihan Chen, MS852 93675825
Find similar trials
Related Studies
- Baltimore Longitudinal Study of AgingRecruiting · National Institute on Aging (NIA) · Baltimore, Maryland
- The Lake Nona Life ProjectRecruiting · University of Central Florida · Orlando, Florida
- Technical Development of Multi-Parametric Renocerebral MRIRecruiting · University of Minnesota · Minneapolis, Minnesota
- Influence of Brain Oscillation-Dependent TMS on Motor FunctionRecruiting · National Institute of Neurological Disorders and Stroke (NINDS) · Bethesda, Maryland